Regeneron Pharmaceuticals Inc.

The sponsor is active in immune-mediated conditions affecting the skin, lungs, and gastrointestinal tract, with trials in atopic dermatitis, asthma, bullous pemphigoid, eosinophilic gastritis, and severe IgE-mediated food allergy. Its portfolio also includes noninfectious uveitis, lupus nephritis, and pulmonary arterial hypertension, reflecting a broad focus on inflammatory and immune dysregulation.

• Atopic dermatitis
• Asthma
• Bullous pemphigoid
• Eosinophilic gastrointestinal disease
• Autoimmune and inflammatory disorders

Research in this area also includes immune-targeted approaches for bullous skin disease, ocular inflammation, and chronic allergic disease across adult and pediatric populations.

Regeneron supports clinical research in paroxysmal nocturnal hemoglobinuria, severe aplastic anemia, hemophilia B, beta-thalassemia, and non-transfusion dependent beta-thalassemia. The sponsor also studies systemic light chain amyloidosis and resultant iron overload, showing interest in rare blood disorders and related complications.

• Paroxysmal nocturnal hemoglobinuria
• Severe aplastic anemia
• Hemophilia B
• Thalassemia and iron overload
• Systemic light chain amyloidosis

These programs include therapies aimed at complement inhibition, hemolysis control, and restoration of hematologic function in rare and complex blood diseases.

The research landscape includes fibrodysplasia ossificans progressiva, Parkinson's disease, and congenital hearing loss linked to OTOF gene variants. In ophthalmology, the sponsor studies geographic atrophy associated with age-related macular degeneration and retinopathy of prematurity, together with noninfectious uveitis as an inflammatory eye disorder.

• Fibrodysplasia ossificans progressiva
• Parkinson's disease
• Congenital hearing loss
• Geographic atrophy
• Retinopathy of prematurity

Its genetic-disease portfolio also includes monogenic obesity and other inherited conditions with defined molecular causes.

Regeneron funds studies in venous thromboembolism, symptomatic venous thromboembolism, and thromboembolic disease, as well as cancer-associated thrombosis and prevention of clotting after orthopedic procedures and catheter placement. The portfolio also includes sepsis-induced hypotension and pulmonary arterial hypertension, indicating interest in vascular and critical care settings.

• Venous thromboembolism
• Cancer-associated thrombosis
• Sepsis-induced hypotension
• Pulmonary arterial hypertension
• Thromboembolic disease

These trials address clot prevention, hemodynamic instability, and vascular complications across surgical, oncologic, and hospitalized patient populations.